Next Phase Newsletter

A healthcare focused fund is headquartered in Shanghai and has presence in US and Europe. The fund has strong preference for early stage opportunities. The senior team members have strong operating experience in biotech and pharma companies, the firm has a strong preference to lead investments and play active contribute to the success in our portfolio companies.

The firm is particularly keen on cardiovascular, regenerative medicine, CNS and hearing related opportunities. The firm is otherwise agnostic in regards to specific disease indications and is willing to look at all early-stage opportunities, however, diagnostics is currently considered as a low priority.

As the firm seeks to be an active lead investor, the firm strongly prefers a board seat in companies. Outside of the board requirement, the firm is looking for a strong management team with passion and capability in advancing the company’s technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A strategic venture capital arm and innovation group of, a large health system with 13 hospitals in Michigan and Ohio is managing both a seed fund as well as a later-stage corporate venture fund, both dedicated to medtech and healthcare IT. In addition, the group also has an incubator and innovation group that looks to develop and integrate IP generated internally and externally that can be leveraged by the health system. Seed investments usually range from $100k – $500k with additional capital reserved for follow on investments, typically allocating up to $1.5M over the life of the investment. Later stage investments are usually in the range of $1M-$2M. The group is flexible in terms of structure but typically refers to convertible notes for seed deals and straight equity for later-stage investments. The firm may lead investments or invest with a syndicate and looks to be active in portfolio companies’ development and add value at the board level as well as through integration into the health system.

The firm is exclusively focused on the medtech and digital health/healthcare IT sectors. The group is fairly opportunistic in these areas, but looks for technologies that can be leveraged by the health system. Both pre-revenue and pre-FDA approval devices, as well as commercial/revenue-generating companies, will be considered. ProMedica has no preference for regulatory pathway and has a particular interest in the cardio space.

The firm has historically focused on startups in the midwestern United States, however, is looking more broadly and open to companies across the U.S. The group favors strong management teams that are open to working closely together.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Established in 2017, a venture capital fund is a $60M+ venture capital partnership and a new addition to its sister fund. The firm is focused on companies that contribute to the delivery of “Delightful Moments”, in other words technologies that enhance the human experience and contribute to their well-being. For initial investment, the firm will invest $100-500K and will reserve some funds for follow-on investment. The firm invests mainly in Seed to Series A rounds and often acts as the first institutional investor. The firm has offices in USA and Western Europe, and expanded into Western Europe in early 2019. Currently, the firm is focused on investing in companies based in the USA and Western Europe.

The firm is interested in companies dedicated to the “technological vectors of happiness”. Such technologies include genetics, microbiome, personal pharmaceuticals/diagnostics, VR/AR, consumer-facing medtech or digital health technologies, etc. Initially, the firm did not invest in traditional biopharmaceuticals or medical devices, but the firm has expanded their interests and now actively seeking opportunities in therapeutics and devices with a focus on early-stage, pre-IND companies.

The firm is open to working with all types of management teams and has no specific management requirements. They could lead the round at seed stage but typically syndicate with other investors for Series A. The firm will take an active role in supporting their companies with needed guidance and resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A private investment firm founded in 2016 is based in New York City, NY and in Asia. The firm’s limited partners include institutional investors from US and China. Currently the firm is investing from its Phase I US$180 million fund into the healthcare sector. Typical equity investments range from US$5-10 million in businesses from Series A to pre-IPO and public traded companies. The firm is open to leading or following a syndicated round. The firm is now seeking opportunities in North America.

The firm invests across therapeutics, medical devices, diagnostics, platform technologies, and healthcare IT and is looking for companies that are top 3 in their niche sector. Within therapeutics, the firm prefers clinical-stage projects. The firm is opportunistic in terms of disease areas including orphan indications. Within device and diagnostics, the firm prefers post-prototype products with clinical validation.

The firm may request board representation or board observership on a case-by-case basis.

The firm is the newly established investment funding arm of a West Coast-based health system. The health system operates 28 hospitals across 6 states. The firm’s objectives include fostering the commercialization of internal ideas as well as external innovation. The firm made its first investment in September 2020, and expect to close 2 more investments in the next 3 months. To date, the firm has been focusing in Series A to B rounds but expect to look into more early-stage opportunities in the future. Initial size of investment can range from $500K – 1M. The firm invests off balance sheet and has no dedicated fund. The firm is focused on partnering and investing in companies based in the USA.

The firm is interested in piloting and investing in technologies that strategically align with the interests of a large integrated delivery network. This includes both the organization’s existing priority areas, along trying to improve the health system’s strategic position in the future. Areas of interest include improving the ratings and member retention in our Medicaid and Medicare Advantage insurance plans, recruiting and retaining clinicians, process optimization, the coming consumerization of healthcare, back-office optimization, and more. The firm is primarily looking for digital health solutions, but will consider some 510k medical devices. The firm is not interested in therapeutics or diagnostics.

The firm has no specific company or management team requirements. The firm prefers to co-invest alongside syndicate partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a venture capital firm based in Vancouver, Canada and actively invests in health technology, sports technology, fitness, and nutrition businesses. The firm is an early-stage investor and focuses on investing in Seed to Series A rounds. The firm makes initial investments up to $100K through equity or convertible notes and will make 2-4 investments per year. The firm is raising a new fund that will focus on companies along the Pacific Coast of the USA and across Canada, but currently focuses on investing in Canada-based companies. With the launch of the new venture fund, the firm will invest up to $500k in first rounds.

The firm is dedicated to investing in preventative health and proactive technology solutions that optimize health, activity and longevity. As social impact and technology investors, the firm is committed to the development of technologies, products and services that both enhance and promote an individual’s ability to stay optimally healthy and active over an entire lifetime. The firm focuses on innovative health technologies including digital health, mobile health, sport technology, wearable technology, and those that help with chronic disease management and corporate wellness initiatives. The firm is very interested in consumer-facing technologies that can enhance health and wellness, quality of care, as well as technologies that could be used in developing preventative health strategies and solutions. The firm does not have minimum revenue requirements and will consider companies in their earliest stages as long as they demonstrate high growth potential. The firm

will not consider therapeutics or diagnostic companies. Medical devices subject to a 510k approval process will be considered.

The firm seeks to invest in private companies developing technologies that positively impact health and wellness. The firm can work with all types of management teams with flexibility, although strong experience and a successful track record is a plus. The firm works closely with their portfolio companies and will provide needed expertise, including access to an international network of strategic advisors to support their growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.